Citius Oncology Beats Fiscal Q3 EPS
Citius Oncology (NASDAQ:CTOR), a biopharmaceutical company focused on cancer treatments, released results for its fiscal third quarter on August 12, 2025. The most pivotal news was an upside surprise on loss per share, reported at ($0.08) GAAP for the quarter, $0.07 better than analyst estimates of ($0.15). As anticipated, revenue remained at $0 for the quarter ahead of the planned fourth quarter commercial launch of LYMPHIR, its lead therapy. The quarter showed lower research and development spending, an uptick in general and administrative costs tied to commercialization, and significant new capital raised, but ended with just $112 in cash. Overall, the quarter highlighted progress toward launch readiness, while raising new concerns about near-term liquidity and ongoing losses.
Source: Analyst estimates for the quarter provided by FactSet.
Citius Oncology is dedicated to advancing cancer treatment with new therapies for unmet needs. Its primary asset is LYMPHIR, a biologic drug for treating relapsed or refractory cutaneous T-cell lymphoma, a rare type of blood cancer. This drug holds orphan status, meaning it targets a small patient population with limited treatment options.
Source Fool.com
